Artificial Intelligence, Machine Learning and a New Epoch for Clinical Trials
Exploring how sponsors are stretching the reach of automation for better development, and why change is both sudden and slow.
As research and development leaders embrace the opportunities of automation, they also contend with its challenges. That is why experts recommend a strategic approach to artificial intelligence (AI) and machine learning (ML) adoption that accounts for the implications of this tech now and in the future.
In this report, Biopharma Dive speaks with Baba Shetty, President of Technology and Data Solutions and Terttu Haring, President of Clinical Sites and Patients at Syneos Health, to better understand current perspectives surrounding AI and ML in clinical trials. It examines disruptive and incremental use cases, outstanding challenges and how sponsors are balancing the knowns and unknowns of a rapidly advancing tech landscape.
Download the report.
Related Content
Looking for exclusive insight?
